Nkarta, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKTX research report →
Companywww.nkartatx.com
Nkarta, Inc. , a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
- CEO
- Paul J. Hastings
- IPO
- 2020
- Employees
- 157
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $200.33M
- P/E
- -2.08
- P/S
- 0.00
- P/B
- 0.73
- EV/EBITDA
- -2.44
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -30.90%
- ROIC
- -32.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-104,084,000 · 4.33%
- EPS
- $-1.41 · 11.88%
- Op Income
- $-121,206,000
- FCF YoY
- 13.64%
Performance & Tape
- 52W High
- $3.65
- 52W Low
- $1.63
- 50D MA
- $2.61
- 200D MA
- $2.23
- Beta
- 0.89
- Avg Volume
- 831.35K
Get TickerSpark's AI analysis on NKTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 15, 26 | HASTINGS PAUL J | sell | 26,046 |
| Jan 15, 26 | Mahmood Nadir | sell | 5,649 |
| Jan 6, 26 | Rose Shawn Marshall | other | 139,000 |
| Jan 6, 26 | Rose Shawn Marshall | other | 70,000 |
| Jan 6, 26 | Mahmood Nadir | other | 80,000 |
| Jan 6, 26 | Mahmood Nadir | other | 160,000 |
| Jan 6, 26 | HASTINGS PAUL J | other | 562,000 |
| Jan 6, 26 | HASTINGS PAUL J | other | 94,000 |
| Jun 23, 25 | Rose Shawn Marshall | other | 500,000 |
| Jun 23, 25 | Rose Shawn Marshall | other | 0 |
Our NKTX Coverage
We haven't published any research on NKTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NKTX Report →